AbbVie ABBV
NYSE ABBV
$285.60 +0.41 (+0.14%)
As of: Oct 23, 2026 · 3:59 PM EDT

AbbVie (ABBV) Gains from Sales and Divestitures (2022)

Updated

AbbVie's Gains from Sales and Divestitures was $172 million in FY2022, up 152.9% from $68 million in FY2021.

Analysis

AbbVie (ABBV) Gains from Sales and Divestitures (2022) Analysis & Trends

  • Gains from Sales and Divestitures shows a three-year compound annual growth rate of -19.5% (FY2019 to FY2022).
  • The FY2022 figure marks the highest annual Gains from Sales and Divestitures since FY2019.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $68 million in FY2021 and $330 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Vertex Pharmaceuticals 133.09 Bn 105.09 Bn 2.84 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 172.00 Mn
API Access

AbbVie Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ABBV&period=max&api_key=YOUR_API_KEY